BioMarin Unveils News Data From Late-Stage Hemophilia A Gene Therapy Candidate

  • BioMarin Pharmaceutical Inc BMRN has announced new data from GENEr8-1 Phase 3 study for valoctocogene roxaparvovec, investigational gene therapy for severe hemophilia A.
  •  Data were presented at the International Society on Thrombosis and Haemostasis (ISTH) 2021 Virtual Congress. 
  • Top-line one-year results from this study were previously communicated in January 2021.
  • New data presented include more details on annualized bleeding rate (ABR) in all study participants and annualized Factor VIII utilization rate.
  • Over 90% (N=134) of all participants in the GENEr8-1 study had an ABR of zero or a lower bleed rate than baseline after week four after the treatment. 
  • Mean annualized Factor VIII utilization rate decreased from baseline on Factor VIII prophylaxis by 99% from 3961.2 to 56.9 after week four after treatment with valoctocogene roxaparvovec.
  • As previously shared in January 2021, a single dose of valoctocogene roxaparvovec significantly reduced mean ABR by 84% from a prospectively collected 4.8 baseline to 0.8 bleeding episodes per year.
  • Study participants also experienced a clinically meaningful increase in endogenous Factor VIII expression. 
  • Last week, the European Medicines Agency validated BioMarin's resubmission of a marketing application for the gene therapy.
Loading...
Loading...
BMRN Logo
BMRNBiomarin Pharmaceutical Inc
$58.06-0.09%

Stock Score Locked: Edge Members Only

Benzinga Rankings give you vital metrics on any stock – anytime.

Unlock Rankings
Edge Rankings
Momentum
27.01
Growth
Not Available
Quality
31.24
Value
64.40
Price Trend
Short
Medium
Long
Market News and Data brought to you by Benzinga APIs

Posted In:
Comments
Loading...